Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection.
Ten young adult patients with chronic hepatitis B virus infection and positive hepatitis B e antigen and DNA polymerase (DNAP) levels were treated with alternating courses of seven to 28 days of 5 to 7.5 mg/kg of vidarabine monophosphate (adenine arabinoside monophosphate) and 28 days of human leukocyte interferon (IFN-alpha); three different regimens were given on an outpatient basis. All patients with a fall in their DNAP level, and the DNAP remained undetectable six months after treatment was stopped in one patient. The major side effect, which most often occurred in those patients receiving 7.5 mg/kg of vidarabine monophosphate, was severe muscular pains. This study demonstrated the feasibility of administering vidarabine monophosphate and interferon to outpatients. Based on data from this and other studies, it is now possible to use a relatively nontoxic regimen that includes 28 days of 5 mg/kg of vidarabine monophosphate in a larger controlled study to answer the question of efficacy.
D000328:Adult; D001088:Arabinonucleotides / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004259:DNA-Directed DNA Polymerase / Q000032:analysis; D004311:Double-Blind Method; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D011897:Random Allocation; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000627:therapeutic use*
D001088:Arabinonucleotides; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D001084:Vidarabine Phosphate; D007372:Interferons; D004259:DNA-Directed DNA Polymerase